EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 417 filers reported holding EXELIXIS INC in Q1 2024. The put-call ratio across all filers is 0.60 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $59,325 | -88.5% | 2,500 | -92.4% | 0.00% | -83.3% |
| Q3 2022 | $515,000 | +442.1% | 32,870 | +682.1% | 0.02% | +500.0% |
| Q1 2022 | $95,000 | +31.9% | 4,203 | +6.6% | 0.00% | +50.0% |
| Q4 2021 | $72,000 | -82.0% | 3,941 | -77.8% | 0.00% | -85.7% |
| Q1 2021 | $401,000 | +105.6% | 17,757 | +123.1% | 0.01% | -33.3% |
| Q3 2020 | $195,000 | +242.1% | 7,959 | +140.6% | 0.02% | -16.0% |
| Q1 2020 | $57,000 | -61.2% | 3,308 | -60.2% | 0.02% | -40.5% |
| Q3 2019 | $147,000 | +182.7% | 8,302 | +244.3% | 0.04% | +200.0% |
| Q2 2019 | $52,000 | +57.6% | 2,411 | +75.0% | 0.01% | +7.7% |
| Q1 2019 | $33,000 | -10.8% | 1,378 | -16.4% | 0.01% | -31.6% |
| Q1 2018 | $37,000 | +146.7% | 1,648 | +227.6% | 0.02% | +72.7% |
| Q4 2017 | $15,000 | +66.7% | 503 | +43.3% | 0.01% | +83.3% |
| Q3 2017 | $9,000 | -75.7% | 351 | -79.2% | 0.01% | -87.5% |
| Q1 2017 | $37,000 | +208.3% | 1,687 | +116.3% | 0.05% | +300.0% |
| Q4 2016 | $12,000 | – | 780 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $320,572,000 | 64.48% |
| Sargent Investment Group, LLC | 432,125 | $9,235,000 | 4.22% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 443,534 | $9,483,000 | 3.52% |
| Bellevue Group AG | 3,878,800 | $82,890,000 | 1.42% |
| CAPITAL MANAGEMENT CORP /VA | 237,855 | $5,083,000 | 1.40% |
| Orbimed Advisors | 3,912,900 | $83,619,000 | 1.30% |
| Portolan Capital Management | 540,590 | $11,552,000 | 1.24% |
| TEALWOOD ASSET MANAGEMENT INC | 139,347 | $2,978,000 | 1.21% |
| Signition LP | 84,120 | $1,798,000,000 | 1.18% |
| Penn Capital Management Company, LLC | 529,630 | $11,318,000 | 1.12% |